NCT07216105 2026-04-07
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
Fate Therapeutics
DualityBio Inc.
NRG Oncology
Peking Union Medical College
Cancer Research UK